Evidence map›Paper›PMID 33424840›Full record

Trial reportFrontiers in immunology2020

Immunomodulation Induced During Interferon-α Therapy Impairs the Anti-HBV Immune Response Through CD24

Binqing Fu, Dongyao Wang, Xiaokun Shen, Chuang Guo, Yanyan Liu, Ying Ye, Rui Sun, Jiabin Li, Zhigang Tian, Haiming Wei

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Restoration of HBV-specific CD8Signal transduction and targeted therapy · 2021
    Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Advances in Immunotherapy for Hepatitis B.Pathogens (Basel, Switzerland) · 2022
    Review
  9. Article
  10. Neutrophils inhibit CD8World journal of emergency medicine · 2022
    Article
  11. Cytokines and Chemokines in HBV Infection.Frontiers in molecular biosciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Binqing FuDivision of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, China.
Dongyao WangDivision of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, China.
Xiaokun ShenDivision of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, China.
Chuang GuoDivision of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, China.
Yanyan LiuDepartment of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Ying YeDepartment of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Rui SunDivision of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, China.
Jiabin LiDepartment of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Zhigang TianDivision of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, China.
Haiming WeiDivision of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, China.
University of Science and Technology of China · CNFirst Affiliated Hospital of Anhui Medical University · CNAnhui Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type I interferon is widely used for antiviral therapy, yet has yielded disappointing results toward chronic HBV infection. Here we identify that PEG-IFNα-2b therapy toward persistent infection in humans is a double-edged sword of both immunostimulation and immunomodulation. Our studies of this randomised trial showed persistent PEG-IFNα-2b therapy induced large number of CD24

Indexed as

ADP-ribosyl Cyclase 1Antiviral AgentsBiomarkersB-Lymphocyte SubsetsCD24 AntigenCytokinesHepatitis BHepatitis B virusHost-Pathogen InteractionsHumansImmunomodulationInterferon-alphaInterferon alpha-2Membrane GlycoproteinsPolyethylene GlycolsRecombinant ProteinsADP-ribosyl Cyclase 1Antiviral AgentsBiomarkersCD24 AntigenCD24 protein, humanCD38 protein, humanCytokinesInterferon-alphaInterferon alpha-2Membrane Glycoproteinspeginterferon alfa-2bPolyethylene GlycolsRecombinant Proteinsanti-virus functionCD24+CD38hi Bchronic hepatitis B virus infectionimmunomodulatory effectsPeg-IFNα-2b

Identifiers

PMID33424840
PMCPMC7786281
OpenAlexW3115186616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.